Scarica l'app Stockscreener
260.95
0.79%
2.04
Dopo l'orario di chiusura:
260.95
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KRYS Giù?
Forum
Previsione
Precedente Chiudi:
$258.91
Aprire:
$252.62
Volume 24 ore:
203.76K
Relative Volume:
0.70
Capitalizzazione di mercato:
$7.63B
Reddito:
$389.13M
Utile/perdita netta:
$204.83M
Rapporto P/E:
38.13
EPS:
6.8443
Flusso di cassa netto:
$188.91M
1 W Prestazione:
+3.80%
1M Prestazione:
+0.83%
6M Prestazione:
+43.62%
1 anno Prestazione:
+44.17%
Intervallo 1D:
$252.62
$260.99
Intervallo di 1 settimana:
$242.00
$264.00
Portata 52W:
$122.80
$298.30
Krystal Biotech Inc Stock (KRYS) Company Profile
Nome
Krystal Biotech Inc
Settore
Industria
Telefono
(412) 586-5830
Indirizzo
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
260.95 | 7.63B | 389.13M | 204.83M | 188.91M | 6.8443 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-27 | Iniziato | Wolfe Research | Peer Perform |
| 2026-01-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-05 | Iniziato | Jefferies | Buy |
| 2024-08-06 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-20 | Iniziato | Goldman | Buy |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-12 | Iniziato | Citigroup | Buy |
| 2023-09-07 | Iniziato | Berenberg | Buy |
| 2023-04-18 | Iniziato | Stifel | Buy |
| 2023-02-28 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-18 | Iniziato | BofA Securities | Buy |
| 2021-07-20 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-18 | Iniziato | B. Riley FBR | Buy |
| 2020-06-04 | Iniziato | Evercore ISI | Outperform |
| 2019-09-24 | Iniziato | Goldman | Neutral |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-24 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-30 | Iniziato | Guggenheim | Buy |
| 2018-09-11 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Krystal Biotech Inc Borsa (KRYS) Ultime notizie
KRYS | Krystal Biotech, Inc. Common Executive Compensation - Quiver Quantitative
Krystal Biotech, Inc. ($KRYS) CEO 2025 Pay Revealed - Quiver Quantitative
KRYS PE Ratio & Valuation, Is KRYS Overvalued - intellectia.ai
[DEF 14A] Krystal Biotech, Inc. Definitive Proxy Statement - Stock Titan
SG Americas Securities LLC Purchases 15,591 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
3 Insider-Owned Growth Companies With Up To 81% Earnings Expansion - simplywall.st
KRYS Forecast, Price Target & Analyst Ratings | KRYSTAL BIOTECH INC (NASDAQ:KRYS) - ChartMill
KRYS News & Events - intellectia.ai
BSP:K1YS34 PB Ratio: 0.20 — 96% Below Median - GuruFocus
Exploring Three High Growth Tech Stocks In The US Market - simplywall.st
(KRYS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Krystal Biotech stock price forecast: consolidation likely as KRYS hovers near key support and down 2.39% - Traders Union
Assessing Krystal Biotech (KRYS) Valuation After Recent Share Price Weakness - finance.yahoo.com
Krystal Biotech (NASDAQ:KRYS) Coverage Initiated at Wolfe Research - Defense World
Krystal Biotech (BSP:K1YS34) Cyclically Adjusted PB Ratio : (As of Apr. 01, 2026) - GuruFocus
Krystal Biotech (BSP:K1YS34) EBITDA per Share : R$30.92 (TTM As of Dec. 2025) - GuruFocus
Krystal Biotech (BSP:K1YS34) Gross Property, Plant and Equipment : R$1,033 Mil (As of Dec. 2025) - GuruFocus
Krystal Biotech (BSP:K1YS34) Minority Interest : R$0.00 Mil (As of Dec. 2025) - GuruFocus
Krystal Biotech Inc Phase 1/2 Clinical Trial of KB103 Final Update Call Transcript - GuruFocus
Krystal Biotech Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Q3 2024 Krystal Biotech Inc Earnings Call Transcript - GuruFocus
Krystal Biotech Inc (BSP:K1YS34) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Krystal Biotech (BSP:K1YS34) Shiller PE Ratio : (As of Mar. 28, 2026) - GuruFocus
BSP:K1YS34 Pretax Margin %: 47.74% — 45% Above Median - GuruFocus
Krystal Biotech (BSP:K1YS34) Unearned Premiums - GuruFocus
BSP:K1YS34 Graham Number: R$439.15 — 14786% Above Median - GuruFocus
Krystal Biotech Inc (BSP:K1YS34) Dividend - GuruFocus
Krystal Biotech Inc FDA Approval Call Transcript - GuruFocus
Krystal Biotech (BSP:K1YS34) Cyclically Adjusted PS Ratio : (As of Mar. 28, 2026) - GuruFocus
Krystal Biotech (BSP:K1YS34) Other Current Payables : R$-0 Mil (As of Dec. 2025) - GuruFocus
Krystal Biotech (BSP:K1YS34) Pre-Tax Income : R$1,047 Mil (TTM As of Dec. 2025) - GuruFocus
Krystal Biotech (BSP:K1YS34) Non Operating Income : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
BSP:K1YS34 Net Income From Continuing Operations: R$1,124 Mi - GuruFocus
Krystal Biotech Inc KB301 Phase 1 POC Efficacy Data Update Call Transcript - GuruFocus
Krystal Biotech (BSP:K1YS34) Net Income (Discontinued Opera - GuruFocus
Q4 2024 Krystal Biotech Inc Earnings Call Transcript - GuruFocus
Krystal Biotech (BSP:K1YS34) Cyclically Adjusted Price-to-F - GuruFocus
Krystal Biotech Inc Stock Intrinsic Values | BSP:K1YS34 - GuruFocus
Krystal Biotech Inc (BSP:K1YS34) Stock Price, Trades & News - GuruFocus
Q2 2024 Krystal Biotech Inc Earnings Call Transcript - GuruFocus
Krystal Biotech (BSP:K1YS34) Gross-Profit-to-Asset % : 31.50% (As of Dec. 2025) - GuruFocus
Krystal Biotech Inc (BSP:K1YS34) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Krystal Biotech Inc (BSP:K1YS34)Valuation Measures & Financial Statistics - GuruFocus
Krystal Biotech (BSP:K1YS34) Fees and Other Income - GuruFocus
Krystal Biotech (BSP:K1YS34) Degree of Operating Leverage : 1.66 (As of Dec. 2025) - GuruFocus
Krystal Biotech (BSP:K1YS34) Degree of Financial Leverage : 2.28 (As of Dec. 2025) - GuruFocus
Krystal Biotech Inc (BSP:K1YS34) Competitors 2026 - GuruFocus
Krystal Biotech Inc (BSP:K1YS34) Valuation - GuruFocus
Krystal Biotech (BSP:K1YS34) ROE % : 17.59% (As of Dec. 2025) - GuruFocus
Krystal Biotech Inc Stock Historical Valuations - GuruFocus
Krystal Biotech Inc (BSP:K1YS34) Stock News, Headlines & Updates - GuruFocus
Krystal Biotech Inc Azioni (KRYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):